Press Releases

CARLSBAD, Calif., Dec. 19, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapeutics, announced today that Biogen, a collaboration partner for neurological diseases, has licensed IONIS-MAPTRx, an antisense therapy designed to selectively reduce production of microtubule-associated protein tau (MAPT), or tau,

REDWOOD CITY, Calif., Dec. 19, 2019 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that D. Keith Grossman, Nevro's Chairman, CEO and President, will present at the 38th Annual J.P. Morgan

GAITHERSBURG, Md., Dec. 19, 2019 /PRNewswire/ -- MaxCyte, the global clinical-stage cell-based therapies and life sciences company, announced today that Shruti Abbato has joined the Company as Executive Vice President, Business Development for CARMA Cellular Therapies. Ms. Abbato will lead development of new partnerships for the Company's CARMA platform programmes.&

VANCOUVER, British Columbia, Dec. 19, 2019 /PRNewswire/ -- Sunniva Inc. ("Sunniva", "we", "our" or the "Company") (CSE:SNN, OTCQB:SNNVF) and Cura-Can Health Corp. ("Cura-Can") are pleased to announce the closing of the previously reported sale (the "Transaction") of Sunniva's wholly-owned subsidiary, Natural Health Services Ltd. ("NHS") on

NEW YORK, Dec. 19, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH) ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies for dermatological disorders such as atopic dermatitis, chronic wounds, psoriasis and acne, today announced entering into a research collaboration agreement with Weill Cornell Medicine to

PITTSBURGH, Dec. 19, 2019 /PRNewswire/ -- ANSYS (NASDAQ: ANSS) will showcas

REHOVOT, Israel, Dec. 19, 2019 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative medicine company, today announced that Yehiel Tal, Chief Executive Officer of CollPlant Biotechnologies, has issued a Letter to Shareholders, the full text of which follows below.

State-of-the-art manufacturing facility will support clinical and commercial production of cell therapies for thousands of patients annually worldwide Global commercial-scale facility is designed to comply with cGMP guidelines in the U.S., Europe and Asia Facility will integrate digital technology to enable real-time

WARSAW, Ind., Dec. 19, 2019 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its fourth quarter sales and earnings conference call will be broadcast over the Internet on Tuesday, February 4, 2020, at 8:30 a.m. Eastern Time.  A news release detailing the quarterly results will

First Tazarotene Acne Treatment Approved in Lotion Formulation BRIDGEWATER, N.J., Dec. 19, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced that the U.S. Food and Drug Administration (FDA) has approved